دورية أكاديمية
Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week.
| العنوان: | Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week. |
|---|---|
| المؤلفون: | Boden WE; VA Boston Healthcare System, Boston, Massachusetts, USA; Boston University School of Medicine, Boston, Massachusetts, USA. Electronic address: william.boden@va.gov., Marzilli M; Cardiology Department, University of Pisa, Pisa, Italy., Crea F; Department of Cardiology, Catholic University, Rome, Italy., Mancini GBJ; Department of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada., Weintraub WS; MedStar Health Research Institute, Georgetown University, Washington, DC, USA., Taqueti VR; Division of Cardiovascular Medicine and Imaging, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Pepine CJ; Division of Cardiovascular Medicine, University of Florida School of Medicine, Gainesville, Florida, USA., Escaned J; Hospital Clinico San Carlos IDISSC, Complutense University, Madrid, Spain., Al-Lamee R; Imperial College London, London, United Kingdom., Gowdak LHW; Heart Institute, University of São Paulo Medical School, São Paulo, Brazil., Berry C; University of Glasgow, Glasgow, Scotland, United Kingdom., Kaski JC; Molecular and Clinical Sciences Research Institute, St George's University of London, London, United Kingdom. |
| مؤلفون مشاركون: | Chronic Myocardial Ischemic Syndromes Task Force |
| المصدر: | Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Feb 07; Vol. 81 (5), pp. 505-514. |
| نوع المنشور: | Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Biomedical Country of Publication: United States NLM ID: 8301365 Publication Model: Print Cited Medium: Internet ISSN: 1558-3597 (Electronic) Linking ISSN: 07351097 NLM ISO Abbreviation: J Am Coll Cardiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [New York, N.Y.] : Elsevier Biomedical, [c1983- |
| مواضيع طبية MeSH: | Myocardial Ischemia*/diagnosis , Myocardial Ischemia*/epidemiology , Myocardial Ischemia*/therapy , Coronary Artery Disease*/diagnosis , Coronary Artery Disease*/therapy , Coronary Artery Disease*/complications , Vascular Diseases*/complications, Humans ; Angina Pectoris |
| مستخلص: | Management of stable coronary artery disease (CAD) has been based on the assumption that flow-limiting atherosclerotic obstructions are the proximate cause of angina and myocardial ischemia in most patients and represent an important target for revascularization. However, the role of revascularization in reducing long-term cardiac events in these patients has been limited mainly to those with left main disease, 3-vessel disease with diabetes, or decreased ejection fraction. Mounting evidence indicates that nonepicardial coronary causes of angina and ischemia, including coronary microvascular dysfunction, vasospastic disorders, and derangements of myocardial metabolism, are more prevalent than flow-limiting stenoses, raising concerns that many important causes other than epicardial CAD are neither considered nor probed diagnostically. There is a need for a more inclusive management paradigm that uncouples the singular association between epicardial CAD and revascularization and better aligns diagnostic approaches that tailor treatment to the underlying mechanisms and precipitants of angina and ischemia in contemporary clinical practice. Competing Interests: Funding Support and Author Disclosures This publication was supported by an educational grant from Servier, Suresnes Cedex, France. Support in the development of the manuscript was also provided by Liberum IME, London, United Kingdom. Dr Boden receives research grant support from AbbVie, Amarin Pharmaceuticals, Amgen, AstraZeneca, Sanofi, Massachusetts Veterans Epidemiology Research and Information Center, VA New England Healthcare System’s Clinical Trials Network, and the National Heart, Lung, and Blood Institute (NHLBI), where he served as national co-principal investigator for the ISCHEMIA trial; is on the Board of Directors for the Boston VA Research Institute; receives consulting fees from Amarin Pharmaceuticals, Amgen, Janssen Pharmaceuticals, Metuchen Pharmaceuticals, and Servier; is on the VA Cooperative Studies Program data monitoring committee; and has received speaking honoraria from Amarin, Amgen, Janssen Pharmaceuticals, Pfizer, and Servier. Dr Marzilli lectures for Servier, Menarini, Degussa Pharma Group, Baldacci, Abbott, and AstraZeneca. Dr Crea has received personal speaker fees from Amgen, AstraZeneca, Servier, and BMS; and is a member of the advisory board for GlyCardial Diagnostics. Dr Mancini has received grants, advisory board appointments, and honoraria for educational lectures from Amgen, Sanofi, NovoNordisk, Lilly/Boehringer Ingelheim, and HLI Therapeutics; is on the advisory board for Esperion; and receives reports on grants from the National Institutes of Health (NIH) for the COURAGE and ISCHEMIA trials. Dr Weintraub has received research support from Amarin Corporation, NIH, and Centers for Disease Control and Prevention; and has served as a consultant for Amarin Corporation, AstraZeneca, Pfizer, Janssen, SC Pharma, Lexicon, Faraday, and The Medicines Company. Dr Taqueti is supported by NIH grant K23HL135438. Dr Pepine receives research grant support from NIH/NHLBI (R21AG063143, K08 HL130945, K01 HL138172, R01 HL146158, AG065141, R01 HL152162, R21 HL152264, R01 HL132448, UM1 HL087366, UM1 HL087318), NIH/National Center for Advancing Translational Sciences (UL1 TR001427), U.S. Department of Defense (W81XWH-17-2-0030, WARRIOR), Biocardia, Brigham and Women’s Hospital, CSL Behring, Cytori Therapeutics, DCRI, GE Healthcare, Mesoblast, and Pfizer; receives consultant fees/honoraria from Caladrius Biosciences, Slack, and Xylocor; and receives grant support from the Gatorade Foundation through the University of Florida Department of Medicine and from the McJunkin Family Foundation, Plantation, Florida. Dr Escaned has received speaker and advisory board honoraria from Abbott Laboratories and Philips. Dr Al-Lamee has received speaker honoraria from Philips Volcano, Abbott Vascular, and Menarini Pharmaceuticals. Dr Gowdak has received congress-related travel expenses from Servier; has participated in clinical trials sponsored by Servier and Angion Biomedica; has been a speaker for Servier, Boehringer-Lilly, and Abbott; is an advisory board member for Servier; and has prepared written scientific material for Servier and Abbott. Dr Berry is employed by the University of Glasgow, which holds consultancy and research agreements for his work with Abbott Vascular, AstraZeneca, Auxilius Pharma, Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GSK, HeartFlow, Menarini, Neovasc, Siemens Healthcare, and Valo Health; and receives research funding from the British Heart Foundation (grant RE/18/6134217), Chief Scientist Office, Engineering and Physical Sciences Research Council (EP/R511705/1, EP/S030875/1), European Union (754946-2), Medical Research Council (MR/S018905/1), and UKRI (MC/PC/20014). Dr Kaski has received speaker honoraria from A. Menarini Farmaceutica lnternazionale, Servier, and Bayer UK. Dr Escaned has reported that he has no relationships relevant to the contents of this paper to disclose. (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.) |
| References: | Int J Cardiol. 2015;186:29-31. (PMID: 25804461) Circulation. 2021 Aug 17;144(7):512-523. (PMID: 34261331) N Engl J Med. 2020 Apr 9;382(15):1408-1419. (PMID: 32227753) Eur J Prev Cardiol. 2013 Oct;20(5):743-9. (PMID: 22547410) Nat Rev Cardiol. 2018 Feb;15(2):120-132. (PMID: 28880025) J Am Coll Cardiol. 2021 Nov 30;78(22):e187-e285. (PMID: 34756653) Circ Cardiovasc Qual Outcomes. 2009 Mar;2(2):134-40. (PMID: 20031826) JACC Cardiovasc Imaging. 2019 Oct;12(10):1958-1969. (PMID: 30772231) N Engl J Med. 2020 Apr 9;382(15):1395-1407. (PMID: 32227755) Am Heart J. 2003 Jan;145(1):47-57. (PMID: 12514654) Circulation. 2015 Apr 7;131(14):1269-77. (PMID: 25847979) Cardiovasc Res. 2020 Mar 1;116(4):771-786. (PMID: 31958128) J Am Coll Cardiol. 2012 Sep 11;60(11):951-6. (PMID: 22954239) Sci Rep. 2022 Mar 24;12(1):5138. (PMID: 35332253) Lancet. 2015 Jun 13;385(9985):2383-91. (PMID: 25788230) N Engl J Med. 2009 Jun 11;360(24):2503-15. (PMID: 19502645) Int J Cardiol. 2018 Jan 1;250:16-20. (PMID: 29031990) Circulation. 2020 Mar 10;141(10):787-789. (PMID: 32150469) Catheter Cardiovasc Interv. 2016 Dec;88(7):1017-1024. (PMID: 26774951) J Am Coll Cardiol. 2019 Nov 12;74(19):2350-2360. (PMID: 31699275) Eur Heart J. 2021 Apr 7;42(14):1394-1400. (PMID: 33827137) J Nucl Cardiol. 2023 Aug;30(4):1739-1744. (PMID: 35149975) Am J Med. 2017 Nov;130(11):1259-1261. (PMID: 28797644) Lancet. 2022 Feb 12;399(10325):691-694. (PMID: 35033221) Curr Opin Cardiol. 2017 Sep;32(5):627-632. (PMID: 28797011) Circ Cardiovasc Qual Outcomes. 2018 Mar;11(3):e004665. (PMID: 29530888) J Am Acad Nurse Pract. 2009 Jan;21(1):47-53. (PMID: 19125895) Circulation. 2011 Aug 23;124(8):967-90. (PMID: 21788592) JACC Cardiovasc Interv. 2020 Jan 13;13(1):33-45. (PMID: 31709984) N Engl J Med. 2007 Apr 12;356(15):1503-16. (PMID: 17387127) N Engl J Med. 2010 Mar 11;362(10):886-95. (PMID: 20220183) Circulation. 2018 May 22;137(21):2218-2230. (PMID: 29581125) N Engl J Med. 2014 Sep 25;371(13):1208-17. (PMID: 25176289) Circulation. 2018 Oct 2;138(14):1463-1480. (PMID: 30354347) IEEE Access. 2021;9:52796-52811. (PMID: 33996344) Circulation. 2015 Jan 6;131(1):19-27. (PMID: 25400060) J Manag Care Spec Pharm. 2016 Jan;22(1):56-62. (PMID: 27015052) Circulation. 2017 Dec 12;136(24):2325-2336. (PMID: 28864442) Eur Heart J. 2020 Jan 14;41(3):407-477. (PMID: 31504439) J Am Coll Cardiol. 2021 Aug 17;78(7):713-736. (PMID: 34384554) Int J Cardiol. 2020 Apr 1;304:5-7. (PMID: 31982164) Lancet. 2018 Jan 6;391(10115):31-40. (PMID: 29103656) J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129. (PMID: 34895950) Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005455. (PMID: 31665896) Eur Heart J. 2019 Aug 1;40(29):2455-2462. (PMID: 30608528) Int J Cardiol. 2022 Apr 1;352:9-18. (PMID: 35120946) J Nucl Cardiol. 2022 Aug;29(4):1763-1775. (PMID: 35534718) Coron Artery Dis. 2022 Mar 1;33(2):91-97. (PMID: 33878073) Crit Pathw Cardiol. 2019 Dec;18(4):167-175. (PMID: 31725507) J Am Coll Cardiol. 2018 Nov 27;72(21):2625-2641. (PMID: 30466521) Circ Cardiovasc Qual Outcomes. 2008 Sep;1(1):12-20. (PMID: 20031783) |
| معلومات مُعتمدة: | RE/18/6134217 United Kingdom BHF_ British Heart Foundation; U54 AG065141 United States AG NIA NIH HHS; UL1 TR001427 United States TR NCATS NIH HHS; R01 HL132448 United States HL NHLBI NIH HHS; MR/S018905/1 United Kingdom MRC_ Medical Research Council; UM1 HL087366 United States HL NHLBI NIH HHS; R21 HL152264 United States HL NHLBI NIH HHS; R01 HL152162 United States HL NHLBI NIH HHS; R01 HL146158 United States HL NHLBI NIH HHS; K23 HL135438 United States HL NHLBI NIH HHS; K01 HL138172 United States HL NHLBI NIH HHS; PG/17/25/32884 United Kingdom BHF_ British Heart Foundation; K08 HL130945 United States HL NHLBI NIH HHS; UM1 HL087318 United States HL NHLBI NIH HHS; R21 AG063143 United States AG NIA NIH HHS |
| فهرسة مساهمة: | Keywords: coronary microvascular dysfunction; epicardial coronary artery disease; myocardial ischemia; percutaneous coronary intervention; revascularization; stable angina |
| تواريخ الأحداث: | Date Created: 20230201 Date Completed: 20230203 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10561495 |
| DOI: | 10.1016/j.jacc.2022.08.814 |
| PMID: | 36725179 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1558-3597 |
|---|---|
| DOI: | 10.1016/j.jacc.2022.08.814 |